Mark DeLong - Aug 4, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Senior Vice President
Signature
/s/ David Watson, attorney-in-fact for Mark Delong
Stock symbol
APLS
Transactions as of
Aug 4, 2022
Transactions value $
-$452,300
Form type
4
Date filed
8/8/2022, 04:02 PM
Previous filing
Jul 28, 2022
Next filing
Aug 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $155K +10K +34.19% $15.52 39.3K Aug 4, 2022 Direct F1
transaction APLS Common Stock Sale -$298K -5K -12.74% $59.50 34.3K Aug 4, 2022 Direct F1
transaction APLS Common Stock Sale -$310K -5K -14.6% $62.00 29.3K Aug 4, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -10K -40% $0.00 15K Aug 4, 2022 Common Stock 10K $15.52 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale from an established 10B5-1 trading plan.
F2 This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.